The Use of Real-World Evidence in Health Technology Assessments by the Canadian Agency for Drugs and Technologies in Health Increasingly real-world data (RWD) are being used to inform decision-making in health technology assessments (HTAs) by providing information...
Gene Therapy: International Regulatory and Health Technology Assessment (HTA) Activities and Reimbursement Status Gene therapy is a growing area of interest for the treatment of several diseases. These therapies are intended to offer a one-time treatment to modify a...
On March 4th, 2019, Medlior attended the regional Women in Data Science event, hosted by the Cumming School of Medicine at the University of Calgary. Women in Data Science (WiDS) is an internationally-broadcasted event hosted at Stanford University and has spurred...
CAR-T Therapy: Challenges for Implementation in Canada In 2017, autologous chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah®, Novartis), became the first gene therapy approved in the United States for acute lymphoblastic leukemia in children...
Alberta’s administrative health system data covers 4.2 million residents and includes pharmacy-level drug claims data and province-wide laboratory data. Community researchers, such as Medlior, have direct access to de-identified health system data in Alberta for ethics-approved industry-sponsored research.
Bell Let’s Talk Day is an amazing initiative that is helping to end the stigma of mental health as well as raise fund for research initiatives. Here’s how programs like this can help bridge the current data gap that exists in the mental health sector. #BellLetsTalk
For patients with migraines, it is more than just a headache. As new therapies enter the market, improvements may be seen in medication adherence with a subsequent improvement in the burden of disease, healthcare utilization and costs.
After tremendous growth and success in 2018, Medlior is looking forward to tackling 2019 with a mindset of innovation and enthusiasm!
One of the reasons our team loves working at Medlior is our core purpose of positively impacting global health through rigorous research, and we look forward to contributing more towards our goal this year.
Our work within the healthcare industry offers us a unique perspective on upcoming initiatives and trends and we’ve put together 6 predictions we think you will see in 2019.
Medlior’s Top Insights from 2018 Looking back at 2018 through the world of health outcomes research. 2018 has been a fantastic year, we’ve seen some amazing biotech innovations and breakthroughs in many areas of clinical research. The Medlior team is interested to see...
Understanding Canadian Insurance Coverage and the discrepancy in current data The proportions of public and private prescription drug coverage vary substantially between provinces in Canada. Variations in prescription drug coverage in different provinces can likely be...